| Abstrakt: |
Background: Contrast-induced nephropathy (CIN) after percutaneous coronary intervention (PCI) is associated with prolonged hospitalization along with long-term mortality and morbidity rates and increased financial expenditure. Diabetes is already a well known risk factor for development of CIN after percuataneous coronary intervention. Non-diabetic patients with Metabolic Syndrome (MetS) may have increased risk of developing CIN after PCI. At present, little data exist about the impact of metabolic syndrome as a risk factor in non-diabetic patients after PCI. Aim: The purpose of the study is to evaluate MetS as a risk factor for the development of CIN after elective PCI among hemodynamically stable non-diabetic patients. Materials and methods: This was a single center, prospective, case-control, observational study conducted between March, 2017 and December, 2017. A total of 500 patients were enrolled, out of which 267 patients were included in MetS group and 233 patients were included in Non-Mets group. Data regarding baseline demographic, procedural and angiographic characteristics and hospital outcomes were collected. All the patients were evaluated for the development of CIN after elective PCI. Results: The incidence of CIN was observed in 44 patients (16.8%) in the MetS group and 14 patients (6%) in the Non-MetS group (p=<0.001). MetS(OR: 1.4, 95% CI:2.1-9.3; p=0.03), eGFR<60 ml/min/1.73m2(OR: 13.4, 95% CI:3.9-45.4; p<0.001)and contrast volume>200 ml(OR: 16.7, 95% CI:4.6-57.6; p<0.001)were independent predictors of CIN. The MetS patients who developed CIN had prolonged hospital stay (4.7 ± 1.4 vs.3.7 ± 0.15; p=0.048)and more complicated clinical course than Non-MetS patients. No mortality was observed in both the groups. Conclusion: The MetS was found as a risk factor for the development of CIN after elective PCI among non-diabetic patients. Hence, prior to PCI, the identification of MetS patients are of utmost importance to prevent the incidence of CIN. [ABSTRACT FROM AUTHOR] |
